Why it matters

Pharmaceutical giant Novo Nordisk has dramatically ramped up its Washington influence operation, spending $2.8 million on lobbying in Q1 2025 — a 38.9% jump from previous quarter expenditures. Its disclosures indicate lobbying efforts on topics including obesity treatment coverage, drug pricing reforms, and intellectual property protection.

By the numbers

  • $2.33 million: Spent on in-house lobbying efforts
  • $473,000: Distributed among 11 external lobbying firms
  • 38.9%: Increase from Q4 2024 spending

The lobbying portfolio

Novo Nordisk’s advocacy centers on several interconnected policy areas:

  • Treat and Reduce Obesity Act to expand Medicare coverage for obesity treatments
  • IRA implementation affecting Medicare drug price negotiations
  • 340B Drug Pricing Program reforms
  • PBM Reform Act targeting pharmacy benefit managers
  • Intellectual property protections including positions on the Affordable Prescriptions for Patients Act (S.150)

The team

The company employs a deep bench of Capitol Hill veterans:

  • Brian Edward Branton: Longest-serving Novo Nordisk lobbyist (since 2014) with House committee experience;
  • Sonya C. Clay: Former Legislative Director for Rep. Barbara Lee, and
  • Chad A. Yelinski: Recent addition who previously served as Legislative Director for Fmr. Sen. Kelly Loeffler (now Administrator of the Small Business Administration)

New players

The Q1 filing reveals two freshly contracted firms:

  • Checkmate Government Relations LLC: $90,000
  • Nickles Group LLC: $80,000

These additions complement long-standing relationships with firms like Tarplin, Downs & Young LLC and Williams & Jensen PLLC (both engaged since 2020).

Between the lines

Novo Nordisk’s lobbying surge comes as obesity treatments like Wegovy face scrutiny over pricing and access issues. The company is engaging in policy debates that could determine market expansion for its GLP-1 medications.

The big picture

The nearly 40% increase in quarterly lobbying investment reflects high stakes in the current policy environment. For competitors like Eli Lilly (maker of rival drug Zepbound) and other pharmaceutical stakeholders, Novo Nordisk’s lobbying footprint serves as a significant indicator of industry-wide advocacy priorities.

Spot something wrong? Report an issue with this article